Filing Overview
Xerox Holdings Corporation and Xerox Corporation filed a Form 8-K dated January 10, 2024, reporting the departure and separation arrangements of Joanne Collins Smee. The report was signed and filed on January 12, 2024.
Business Context and Reporting Period
Ms. Collins Smee transitioned from Xerox on December 31, 2023, and ceased serving as Executive Vice President and President, Americas of Xerox Holdings. The filing concerns events occurring around year-end 2023 and a separation agreement executed on January 10, 2024.
Financial and Compensation Matters
- A lump-sum cash payment is due on or before January 31, 2024, equal to two times her annual base salary, target bonus amount, and an amount representing the cost of purchasing outside medical coverage.
- A cash payment of her 2023 short-term incentive bonus is expected in March 2024, subject to company performance and Compensation Committee approval. The filing does not provide a clear dollar amount.
- Subject to COBRA election, dental and vision coverage may continue at active-employee rates for up to 24 months.
- Unvested equity awards under the 2020 Performance Incentive Plan will vest on a pro-rata basis, subject to the agreement and applicable plan terms. The filing does not provide a clear value.
- Xerox will continue life-insurance premium payments for an employer-provided death benefit for up to 24 months.
- Xerox will reimburse tax-preparation services for up to 24 months, capped at $10,000.
The filing does not report revenue, profit, cash flow, margins, debt, liquidity, or other operating financial metrics.
Material Changes, Outlook, and Risks
- The reported executive departure represents a change in senior leadership for Xerox’s Americas operations.
- The separation agreement includes mutual releases of claims and non-disparagement provisions.
- Ms. Collins Smee is subject to non-competition and non-solicitation covenants for 18 months following termination of employment.
- Potential costs to Xerox include the separation payment, the 2023 incentive payment, pro-rata equity vesting, benefit continuation, life-insurance premiums, and tax-preparation reimbursement. The filing does not quantify the aggregate expense or its accounting treatment.
- No company financial guidance, operating outlook, contingencies, or broader restructuring plan is disclosed.
Investor Verification Points
- Review Exhibit 10.1 for the complete separation terms, payment calculations, vesting provisions, and covenant details.
- Verify the amount and approval status of the 2023 short-term incentive payment.
- Assess the financial-statement impact and disclosure of the separation-related obligations.
- Monitor subsequent filings for the appointment of a successor to the President, Americas role and any related operational changes.